Company: AZN
Filing Date: 2025-05-23
Form Type: 6-K
Source: 0001654954-25-006059
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-05-23
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1.

#### Director/PDMR Shareholding
23 May 2025 10:00

<div align='center'>**Transaction by Person Discharging Managerial Responsibilities**</div>

AstraZeneca PLC (the Company) announced that, on 21 May 2025, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 21 May 2020 as part of the award granted to Mr Soriot on 6 March 2020, and reflected the revised limits of the AZPSP, as approved by shareholders at the Company's 2020 Annual General Meeting. The award was subject to a three-year performance period. On